19 October 2006 09:56 [Source: ICIS news]
LONDON (ICIS news)--Swiss biopharmaceutical company Serono said on Wednesday that it had increased net income by 19.8% to $170.6m (€136m) in the third quarter on strong sales of its multiple sclerosis drug Rebif.
Revenues rose 9.5% to $699.1m, boosted by a 19.4% increase in royalty and licensing income, which represented 11.4% of total turnover.
Sales of Rebif rose 18.7% to $374.8m worldwide, and jumped 30.1% in the ?xml:namespace>
Last month, Serono announced its sale to German drug company Merck KGaA in a proposed deal valued at $13.3bn.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|